Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Jan 18;292(6514):159–161. doi: 10.1136/bmj.292.6514.159

Antibody responses to recombinant and plasma derived hepatitis B vaccines.

S E Brown, C Stanley, C R Howard, A J Zuckerman, M W Steward
PMCID: PMC1339034  PMID: 3080114

Abstract

The antibody response to hepatitis B surface antigen (anti-HBs) induced in 25 recipients of a recombinant hepatitis B vaccine derived from yeast was compared with that induced in 25 recipients of a vaccine prepared from hepatitis B surface antigen (HBsAg) derived from plasma. Anti-HBs affinity and specificity were compared using assays of antibody affinity with two different antigens, a complex of the major polypeptide of HBsAg (p25; molecular weight 25 000 daltons) covalently linked to its glycosylated form (gp30) prepared from native purified HBsAg, and a cyclical synthetic peptide representing amino acid residues 139-147 of the major polypeptide of HBsAg and known to represent a major part of an a determinant. There was no difference in anti-HBs affinity or molar antigen binding sites of the antibody measured with either antigen between the two groups. All subjects in both groups produced antibody that bound to the gp30/p25 complex antigen, whereas 22 of the recipients of the plasma derived vaccine compared with 24 of those receiving the yeast derived vaccine produced antibodies that bound to the cyclical synthetic peptide 139-147. These results support the finding of similar levels of anti-HBs, measured by commercial solid phase radioimmunoassay, in the two vaccine groups after three doses of vaccine. These results show no significant difference in the quantity, quality, or specificity of the anti-HBs response induced by the recombinant hepatitis B vaccine and the plasma derived hepatitis B vaccine.

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpers J. H., Steward M. W., Soothill J. F. Differences in immune elimination in inbred mice. The role of low affinity antibody. Clin Exp Immunol. 1972 Sep;12(1):121–132. [PMC free article] [PubMed] [Google Scholar]
  2. Bhatnagar P. K., Papas E., Blum H. E., Milich D. R., Nitecki D., Karels M. J., Vyas G. N. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc Natl Acad Sci U S A. 1982 Jul;79(14):4400–4404. doi: 10.1073/pnas.79.14.4400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blank S. E., Leslie G. A., Clem L. W. Antibody affinity and valence in viral neutralization. J Immunol. 1972 Mar;108(3):665–673. [PubMed] [Google Scholar]
  4. Brown S. E., Howard C. R., Zuckerman A. J., Steward M. W. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet. 1984 Jul 28;2(8396):184–187. doi: 10.1016/s0140-6736(84)90479-3. [DOI] [PubMed] [Google Scholar]
  5. Brown S. E., Howard C. R., Zuckerman A. J., Steward M. W. Determination of the affinity of antibodies to hepatitis B surface antigen in human sera. J Immunol Methods. 1984 Aug 3;72(1):41–48. doi: 10.1016/0022-1759(84)90431-9. [DOI] [PubMed] [Google Scholar]
  6. Davidson M., Krugman S. Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet. 1985 Jan 12;1(8420):108–109. doi: 10.1016/s0140-6736(85)92000-8. [DOI] [PubMed] [Google Scholar]
  7. Feuerhake A., Muller R., Lauchart W., Pichlmayr R., Schmidt F. W. HBV-vaccination in recipients of kidney allografts. Vaccine. 1984 Dec;2(4):255–256. doi: 10.1016/0264-410x(84)90039-2. [DOI] [PubMed] [Google Scholar]
  8. Galibert F., Mandart E., Fitoussi F., Tiollais P., Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature. 1979 Oct 25;281(5733):646–650. doi: 10.1038/281646a0. [DOI] [PubMed] [Google Scholar]
  9. Harford N., Cabezon T., Crabeel M., Simoen E., Rutgers A., De Wilde M. Expression of hepatitis B surface antigen in yeast. Dev Biol Stand. 1983;54:125–130. [PubMed] [Google Scholar]
  10. Hilleman M. R., McAleer W. J., Buynak E. B., McLean A. A. Quality and safety of human hepatitis B vaccine. Dev Biol Stand. 1983;54:3–12. [PubMed] [Google Scholar]
  11. Hughes-Jones N. C. The estimation of the concentration and equilibrium constant of anti-D. Immunology. 1967 May;12(5):565–571. [PMC free article] [PubMed] [Google Scholar]
  12. Ionescu-Matiu I., Kennedy R. C., Sparrow J. T., Culwell A. R., Sanchez Y., Melnick J. L., Dreesman G. R. Epitopes associated with a synthetic hepatitis B surface antigen peptide. J Immunol. 1983 Apr;130(4):1947–1952. [PubMed] [Google Scholar]
  13. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. 1984 Nov 24;2(8413):1174–1175. doi: 10.1016/s0140-6736(84)92740-5. [DOI] [PubMed] [Google Scholar]
  14. Lew A. M. The effect of epitope density and antibody affinity on the ELISA as analysed by monoclonal antibodies. J Immunol Methods. 1984 Aug 3;72(1):171–176. doi: 10.1016/0022-1759(84)90445-9. [DOI] [PubMed] [Google Scholar]
  15. McAleer W. J., Buynak E. B., Maigetter R. Z., Wampler D. E., Miller W. J., Hilleman M. R. Human hepatitis B vaccine from recombinant yeast. Nature. 1984 Jan 12;307(5947):178–180. doi: 10.1038/307178a0. [DOI] [PubMed] [Google Scholar]
  16. Nimmo G. R., Lew A. M., Stanley C. M., Steward M. W. Influence of antibody affinity on the performance of different antibody assays. J Immunol Methods. 1984 Aug 3;72(1):177–187. doi: 10.1016/0022-1759(84)90446-0. [DOI] [PubMed] [Google Scholar]
  17. Papaevangelou G., Dandolos E., Roumeliotou-Karayannis A., Richardson S. C. Immunogenicity of recombinant hepatitis B vaccine. Lancet. 1985 Feb 23;1(8426):455–456. doi: 10.1016/s0140-6736(85)91171-7. [DOI] [PubMed] [Google Scholar]
  18. Pasek M., Goto T., Gilbert W., Zink B., Schaller H., MacKay P., Leadbetter G., Murray K. Hepatitis B virus genes and their expression in E. coli. Nature. 1979 Dec 6;282(5739):575–579. doi: 10.1038/282575a0. [DOI] [PubMed] [Google Scholar]
  19. Peterson D. L. Isolation and characterization of the major protein and glycoprotein of hepatitis B surface antigen. J Biol Chem. 1981 Jul 10;256(13):6975–6983. [PubMed] [Google Scholar]
  20. Prince A. M., Ikram H., Hopp T. P. Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A. 1982 Jan;79(2):579–582. doi: 10.1073/pnas.79.2.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scolnick E. M., McLean A. A., West D. J., McAleer W. J., Miller W. J., Buynak E. B. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA. 1984 Jun 1;251(21):2812–2815. [PubMed] [Google Scholar]
  22. Shih J. W., Gerin J. L. Proteins of hepatitis B surface antigen: amino acid compositions of the major polypeptides. J Virol. 1977 Mar;21(3):1219–1222. doi: 10.1128/jvi.21.3.1219-1222.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Stevens C. E., Alter H. J., Taylor P. E., Zang E. A., Harley E. J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984 Aug 23;311(8):496–501. doi: 10.1056/NEJM198408233110803. [DOI] [PubMed] [Google Scholar]
  24. Stevens C. E., Szmuness W., Goodman A. I., Weseley S. A., Fotino M. Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet. 1980 Dec 6;2(8206):1211–1213. doi: 10.1016/s0140-6736(80)92477-0. [DOI] [PubMed] [Google Scholar]
  25. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Alter H. J., Taylor P. E., DeVera A., Chen G. T., Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982 Dec 9;307(24):1481–1486. doi: 10.1056/NEJM198212093072403. [DOI] [PubMed] [Google Scholar]
  26. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  27. Valenzuela P., Gray P., Quiroga M., Zaldivar J., Goodman H. M., Rutter W. J. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature. 1979 Aug 30;280(5725):815–819. doi: 10.1038/280815a0. [DOI] [PubMed] [Google Scholar]
  28. Valenzuela P., Medina A., Rutter W. J., Ammerer G., Hall B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982 Jul 22;298(5872):347–350. doi: 10.1038/298347a0. [DOI] [PubMed] [Google Scholar]
  29. Young P., Vaudin M., Dixon J., Zuckerman A. J. Preparation of hepatitis B polypeptide micelles from human carrier plasma. J Virol Methods. 1982 Apr;4(3):177–185. doi: 10.1016/0166-0934(82)90046-5. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES